{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:20:49Z","timestamp":1761578449066,"version":"build-2065373602"},"posted":{"date-parts":[[2025,10,22]]},"group-title":"In Review","reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,21]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Accumulation of brain amyloid beta (A\u03b2) is a key pathological hallmark of Alzheimer\u2019s disease (AD) and begins many years before cognitive symptoms. Being able to predict the risk of A\u03b2 accumulation, or the age at which this accumulation exceeds a critical threshold, may enable early intervention and treatment to slow or prevent the onset of AD. We utilised published genome-wide association studies (GWAS) to develop polygenic scores (PGS) based on AD risk (PGS\n                  <sub>risk<\/sub>\n                  ) and resilience (PGS\n                  <sub>resilience<\/sub>\n                  ). We tested whether these could predict (i) whether an individual was an accumulator of A\u03b2 (\u2018Accumulator Status\u2019), and (ii) in accumulators, the age at which brain A\u03b2 is estimated to exceed a threshold of 20 centiloids (CL)(\u2018Estimated Age at onset of A\u03b2\u2019; AAO-A\u03b2) among 2175 participants (1158 with AAO A\u03b2) from the Alzheimer\u2019s Dementia Onset and Progression in International Cohorts (ADOPIC) study. Additionally, we conducted genome-wide association studies (GWAS) of these traits and developed phenotype-specific PGSs using cross-validation (CV). Higher PGS\n                  <sub>risk<\/sub>\n                  was associated with a greater risk of being an accumulator and a younger AAO-A\u03b2. When stratified by number of\n                  <italic>APOE<\/italic>\n                  \u03b54 alleles, PGS\n                  <sub>risk<\/sub>\n                  predicted Accumulator Status in\n                  <italic>APOE<\/italic>\n                  \u03b54 heterozygotes, and AAO-A\u03b2 in \u03b54 non-carriers and heterozygotes, with the same directions of effect as were seen in the whole cohort. PGS\n                  <sub>resilience<\/sub>\n                  was not significantly associated with Accumulator Status, but higher PGS\n                  <sub>resilience<\/sub>\n                  was associated with later AAO-A\u03b2 overall and in \u03b54 heterozygotes. Trait-specific PGSs, developed using CV, were not significantly associated with either trait overall and the direction of association varied across CV folds. Polygenic scores, alongside other risk factors, may be useful for identifying individuals at risk of accumulating A\u03b2, and predicting the age at which this exceeds a critical threshold. This could provide a window for administering disease-modifying treatment or lifestyle interventions to prevent or delay the onset of AD.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7911284\/v1","type":"posted-content","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:01:00Z","timestamp":1761159660000},"source":"Crossref","is-referenced-by-count":0,"title":["Predicting accumulation and age at onset of amyloid-\u03b2 from genetic risk and resilience for Alzheimer\u2019s disease"],"prefix":"10.21203","author":[{"given":"Eleanor K","family":"O'Brien","sequence":"first","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Cox","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierrick","family":"Bourgeat","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tenielle","family":"Porter","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Goudey","sequence":"additional","affiliation":[{"name":"University of Melbourne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D","family":"Doecke","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin L","family":"Masters","sequence":"additional","affiliation":[{"name":"University of Melbourne"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen","family":"Fripp","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwangsik","family":"Nho","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L","family":"Villemagne","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Cruchaga","sequence":"additional","affiliation":[{"name":"Washington University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C","family":"Rowe","sequence":"additional","affiliation":[{"name":"Austin Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J","family":"Saykin","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Dore","sequence":"additional","affiliation":[{"name":"Commonwealth Scientific and Industrial Research Organisation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon M","family":"Laws","sequence":"additional","affiliation":[{"name":"Edith Cowan University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman DS","year":"2021","unstructured":"Knopman DS, et al. Alzheimer disease. Nat reviews Disease primers. 2021;7(1):33.","journal-title":"Nat reviews Disease primers"},{"issue":"5","key":"ref2","first-page":"421","article-title":"The genetic landscape of Alzheimer disease: clinical implications and perspectives","volume":"18","author":"Cauwenberghe C","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Sci. 2016;18(5):421\u201330.","journal-title":"Genet Sci"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study","volume":"12","author":"Villemagne VL","year":"2013","unstructured":"Villemagne VL, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367.","journal-title":"Lancet Neurol"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack CR","year":"2013","unstructured":"Jack CR, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe DJ","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"5054","key":"ref6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy JA","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184\u20135.","journal-title":"Science"},{"year":"2011","author":"Sperling RA","key":"ref7","unstructured":"Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Science translational medicine, 2011. 3(111): p. 111cm33-111cm33."},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1196\/annals.1354.065","article-title":"Alzheimer's disease pathogenesis: role of aging","volume":"1067","author":"Harman D","year":"2006","unstructured":"Harman D. Alzheimer's disease pathogenesis: role of aging. Ann N Y Acad Sci. 2006;1067(1):454\u201360.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","article-title":"Role of genes and environments for explaining Alzheimer disease","volume":"63","author":"Gatz M","year":"2006","unstructured":"Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168\u201374.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000334607","article-title":"Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis","volume":"38","author":"Ward A","year":"2012","unstructured":"Ward A, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1\u201317.","journal-title":"Neuroepidemiology"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","article-title":"APOE genotype and early \u03b2-amyloid accumulation in older adults without dementia","volume":"89","author":"Lim YY","year":"2017","unstructured":"Lim YY, et al. APOE genotype and early \u03b2-amyloid accumulation in older adults without dementia. Neurology. 2017;89(10):1028\u201334.","journal-title":"Neurology"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert J-C","year":"2013","unstructured":"Lambert J-C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452\u20138.","journal-title":"Nat Genet"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle BW","year":"2019","unstructured":"Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing. Nat Genet. 2019;51(3):414\u201330.","journal-title":"Nat Genet"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/ng.803","article-title":"Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease","volume":"43","author":"Hollingworth P","year":"2011","unstructured":"Hollingworth P, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429\u201335.","journal-title":"Nat Genet"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ng.801","article-title":"Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease","volume":"43","author":"Naj AC","year":"2011","unstructured":"Naj AC, et al. Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436\u201341.","journal-title":"Nat Genet"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41398-018-0150-6","article-title":"GWAS on family history of Alzheimer\u2019s disease","volume":"8","author":"Marioni RE","year":"2018","unstructured":"Marioni RE, et al. GWAS on family history of Alzheimer\u2019s disease. Translational psychiatry. 2018;8(1):99.","journal-title":"Translational psychiatry"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","article-title":"Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk","volume":"51","author":"Jansen IE","year":"2019","unstructured":"Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet. 2019;51(3):404\u201313.","journal-title":"Nat Genet"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias","volume":"54","author":"Bellenguez C","year":"2022","unstructured":"Bellenguez C, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genet. 2022;54(4):412\u201336.","journal-title":"Nat Genet"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/brain\/awv231","article-title":"GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer\u2019s disease implicates microglial activation gene IL1RAP","volume":"138","author":"Ramanan VK","year":"2015","unstructured":"Ramanan VK, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer\u2019s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(10):3076\u201388.","journal-title":"Brain"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/s41588-024-01939-9","article-title":"GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia","volume":"56","author":"Shade LM","year":"2024","unstructured":"Shade LM, et al. GWAS of multiple neuropathology endophenotypes identifies new risk loci and provides insights into the genetic risk of dementia. Nat Genet. 2024;56(11):2407\u201321.","journal-title":"Nat Genet"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41380-018-0246-7","article-title":"Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging","volume":"26","author":"Yan Q","year":"2021","unstructured":"Yan Q, et al. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry. 2021;26(1):309\u201321.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamapsychiatry.2020.3049","article-title":"From basic science to clinical application of polygenic risk scores: a primer","volume":"78","author":"Wray NR","year":"2021","unstructured":"Wray NR, et al. From basic science to clinical application of polygenic risk scores: a primer. JAMA psychiatry. 2021;78(1):101\u20139.","journal-title":"JAMA psychiatry"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1038\/s41596-020-0353-1","article-title":"Tutorial: a guide to performing polygenic risk score analyses","volume":"15","author":"Choi SW","year":"2020","unstructured":"Choi SW, Mak TS-H, O\u2019Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc. 2020;15(9):2759\u201372.","journal-title":"Nat Protoc"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40471-015-0055-3","article-title":"Polygenic scores in epidemiology: risk prediction, etiology, and clinical utility","volume":"2","author":"Maher BS","year":"2015","unstructured":"Maher BS. Polygenic scores in epidemiology: risk prediction, etiology, and clinical utility. Curr Epidemiol Rep. 2015;2:239\u201344.","journal-title":"Curr Epidemiol Rep"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani A","year":"2018","unstructured":"Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19(9):581\u201390.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","article-title":"10 years of GWAS discovery: biology, function, and translation","volume":"101","author":"Visscher PM","year":"2017","unstructured":"Visscher PM, et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101(1):5\u201322.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41588-018-0193-x","article-title":"Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits","volume":"50","author":"Zhang Y","year":"2018","unstructured":"Zhang Y, et al. Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat Genet. 2018;50(9):1318\u201326.","journal-title":"Nat Genet"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/ng.608","article-title":"Common SNPs explain a large proportion of the heritability for human height","volume":"42","author":"Yang J","year":"2010","unstructured":"Yang J, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42(7):565\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41398-022-02055-0","article-title":"Polygenic resilience scores capture protective genetic effects for Alzheimer\u2019s disease","volume":"12","author":"Hou J","year":"2022","unstructured":"Hou J, et al. Polygenic resilience scores capture protective genetic effects for Alzheimer\u2019s disease. Translational psychiatry. 2022;12(1):296.","journal-title":"Translational psychiatry"},{"key":"ref30","first-page":"202","volume-title":"The Alzheimer's disease neuroimaging initiative: progress report and future plans","author":"Weiner MW","year":"2010","unstructured":"Weiner MW, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Volume 6. Alzheimer's & Dementia; 2010. pp. 202\u201311. 3e7."},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nic.2005.09.008","article-title":"The Alzheimer's disease neuroimaging initiative","volume":"15","author":"Mueller SG","year":"2005","unstructured":"Mueller SG, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin. 2005;15(4):869\u201377.","journal-title":"Neuroimaging Clin"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization","volume":"74","author":"Petersen RC","year":"2010","unstructured":"Petersen RC, et al. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139.","journal-title":"Neurology"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","article-title":"The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease","volume":"21","author":"Ellis KA","year":"2009","unstructured":"Ellis KA, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):672\u201387.","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3233\/ADR-210005","article-title":"Fifteen years of the australian imaging, biomarkers and lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease","volume":"5","author":"Fowler C","year":"2021","unstructured":"Fowler C, et al. Fifteen years of the australian imaging, biomarkers and lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer\u2019s disease. J Alzheimer's disease Rep. 2021;5(1):443\u201368.","journal-title":"J Alzheimer's disease Rep"},{"year":"2019","author":"LaMontagne PJ","key":"ref35","unstructured":"LaMontagne PJ et al. OASIS-3: longitudinal neuroimaging, clinical, and cognitive dataset for normal aging and Alzheimer disease. MedRxiv, 2019: p. 2019.12. 13.19014902."},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41597-024-03485-9","article-title":"Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center","volume":"11","author":"Fernandez MV","year":"2024","unstructured":"Fernandez MV, et al. Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center. Sci data. 2024;11(1):768.","journal-title":"Sci data"},{"year":"2019","author":"Taliun D","key":"ref37","unstructured":"Taliun D et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. bioRxiv, 2019: p. 563866."},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das S","year":"2016","unstructured":"Das S, et al. Next-generation genotype imputation service and methods. Nat Genet. 2016;48(10):1284\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"Chang CC","year":"2015","unstructured":"Chang CC et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience, 2015. 4(1): p. s13742-015-0047-8.","journal-title":"Gigascience"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell S","year":"2007","unstructured":"Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559\u201375.","journal-title":"Am J Hum Genet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1016\/j.neurobiolaging.2014.04.033","article-title":"Comparison of MR-less PiB SUVR quantification methods","volume":"36","author":"Bourgeat P","year":"2015","unstructured":"Bourgeat P, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36:S159\u201366.","journal-title":"Neurobiol Aging"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","article-title":"Implementing the centiloid transformation for 11C-PiB and \u03b2-amyloid 18F-PET tracers using CapAIBL","volume":"183","author":"Bourgeat P","year":"2018","unstructured":"Bourgeat P, et al. Implementing the centiloid transformation for 11C-PiB and \u03b2-amyloid 18F-PET tracers using CapAIBL. NeuroImage. 2018;183:387\u201393.","journal-title":"NeuroImage"},{"key":"ref43","first-page":"406","volume-title":"Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies","author":"Su Y","year":"2018","unstructured":"Su Y, et al. Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. Volume 19. NeuroImage: Clinical; 2018. pp. 406\u201316."},{"year":"2022","author":"Bourgeat P","key":"ref44","unstructured":"Bourgeat P et al. \u03b2-amyloid PET harmonisation across longitudinal studies: Application to AIBL, ADNI and OASIS3. Neuroimage, 2022. 262: p. 119527."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4757682","author":"Burnham SC","year":"2024","unstructured":"Burnham SC et al. When Does Alzheimer's Disease Start? Robust Estimates Based on Longitudinal A\u03b2-Amyloid-PET in Three Large International Cohorts. Available at SSRN: http:\/\/dx.doi.org\/10.2139\/ssrn.4757682, 2024."},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"giz082","DOI":"10.1093\/gigascience\/giz082","article-title":"PRSice-2: Polygenic Risk Score software for biobank-scale data","volume":"8","author":"Choi SW","year":"2019","unstructured":"Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. Gigascience. 2019;8(7):giz082.","journal-title":"Gigascience"},{"issue":"9","key":"ref47","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/bioinformatics\/btu848","article-title":"PRSice: polygenic risk score software","volume":"31","author":"Euesden J","year":"2015","unstructured":"Euesden J, Lewis CM, O\u2019reilly PF. PRSice: polygenic risk score software. Bioinformatics. 2015;31(9):1466\u20138.","journal-title":"Bioinformatics"},{"key":"ref48","first-page":"1","article-title":"Considering the APOE locus in Alzheimer\u2019s disease polygenic scores in the Health and Retirement Study: a longitudinal panel study","volume":"13","author":"Ware EB","year":"2020","unstructured":"Ware EB, et al. Considering the APOE locus in Alzheimer\u2019s disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. BMC Med Genom. 2020;13:1\u201313.","journal-title":"BMC Med Genom"},{"key":"ref49","volume-title":"R: A Language and Environment for Statistical Computing","author":"Core Team R","year":"2024","unstructured":"Core Team R. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria; 2024."},{"key":"ref50","unstructured":"Posit team, RStudio: Integrated Development Environment for R. 2025, Posit Software, PBC: Boston, MA, USA."},{"issue":"387","key":"ref51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/01621459.1984.10478083","article-title":"Cross-validation of regression models","volume":"79","author":"Picard RR","year":"1984","unstructured":"Picard RR, Cook RD. Cross-validation of regression models. J Am Stat Assoc. 1984;79(387):575\u201383.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-7439(00)00122-2","article-title":"Monte Carlo cross validation","volume":"56","author":"Xu Q-S","year":"2001","unstructured":"Xu Q-S, Liang Y-Z. Monte Carlo cross validation. Chemometr Intell Lab Syst. 2001;56(1):1\u201311.","journal-title":"Chemometr Intell Lab Syst"},{"issue":"5","key":"ref53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/scientificamerican0549-11","article-title":"A study of attitudes","volume":"180","author":"Stouffer S","year":"1949","unstructured":"Stouffer S. A study of attitudes. Sci Am. 1949;180(5):11\u20135.","journal-title":"Sci Am"},{"key":"ref54","first-page":"129","volume-title":"Alzheimer\u2019s polygenic risk scores, APOE, Alzheimer\u2019s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years","author":"Stocker H","year":"2023","unstructured":"Stocker H, et al. Alzheimer\u2019s polygenic risk scores, APOE, Alzheimer\u2019s disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years. Volume 15. Alzheimer's Research & Therapy; 2023. p. 129. 1."},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3233\/JAD-160195","article-title":"Pathway-specific polygenic risk scores as predictors of amyloid-\u03b2 deposition and cognitive function in a sample at increased risk for Alzheimer\u2019s disease","volume":"55","author":"Darst BF","year":"2016","unstructured":"Darst BF, et al. Pathway-specific polygenic risk scores as predictors of amyloid-\u03b2 deposition and cognitive function in a sample at increased risk for Alzheimer\u2019s disease. J Alzheimer\u2019s Disease. 2016;55(2):473\u201384.","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"3","key":"ref56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.25530","article-title":"Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition","volume":"86","author":"Leonenko G","year":"2019","unstructured":"Leonenko G, et al. Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol. 2019;86(3):427\u201335.","journal-title":"Ann Neurol"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/brain\/awv268","article-title":"Common polygenic variation enhances risk prediction for Alzheimer\u2019s disease","volume":"138","author":"Escott-Price V","year":"2015","unstructured":"Escott-Price V, et al. Common polygenic variation enhances risk prediction for Alzheimer\u2019s disease. Brain. 2015;138(12):3673\u201384.","journal-title":"Brain"},{"key":"ref58","first-page":"e12229","volume-title":"Risk of dementia in APOE \u03b54 carriers is mitigated by a polygenic risk score","author":"Ebenau JL","year":"2021","unstructured":"Ebenau JL, et al. Risk of dementia in APOE \u03b54 carriers is mitigated by a polygenic risk score. Volume 13. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring,; 2021. p. e12229. 1."},{"issue":"10","key":"ref59","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000012499","article-title":"Measuring resilience and resistance in aging and Alzheimer disease using residual methods: a systematic review and meta-analysis","volume":"97","author":"Bocancea DI","year":"2021","unstructured":"Bocancea DI, et al. Measuring resilience and resistance in aging and Alzheimer disease using residual methods: a systematic review and meta-analysis. Neurology. 2021;97(10):474\u201388.","journal-title":"Neurology"},{"issue":"15","key":"ref60","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.0000000000005303","article-title":"Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies","volume":"90","author":"Arenaza-Urquijo EM","year":"2018","unstructured":"Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695\u2013703.","journal-title":"Neurology"},{"key":"ref61","first-page":"1","volume-title":"Improving the resistance and resilience framework for aging and dementia studies","author":"Arenaza-Urquijo EM","year":"2020","unstructured":"Arenaza-Urquijo EM, Vemuri P. Improving the resistance and resilience framework for aging and dementia studies. Volume 12. Alzheimer's research & therapy; 2020. pp. 1\u20134."},{"issue":"8","key":"ref62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt K","year":"2016","unstructured":"Schmidt K, et al. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359.","journal-title":"J Lipid Res"},{"issue":"2","key":"ref63","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/18756190MTA4dNjE52","article-title":"The links between cardiovascular diseases and Alzheimer's disease","volume":"19","author":"Leszek J","year":"2021","unstructured":"Leszek J, et al. The links between cardiovascular diseases and Alzheimer's disease. Curr Neuropharmacol. 2021;19(2):152\u201369.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-091561","article-title":"Cardiac disorders as risk factors for Alzheimer's disease","volume":"20","author":"Alves TF","year":"2010","unstructured":"de Alves TF. Cardiac disorders as risk factors for Alzheimer's disease. J Alzheimer\u2019s Disease. 2010;20(3):749\u201363.","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1474-4422(23)00449-0","article-title":"Dementia research in 2023: the year of anti-amyloid immunotherapy","volume":"23","author":"Delrieu J","year":"2024","unstructured":"Delrieu J, Andrieu S, Vellas B. Dementia research in 2023: the year of anti-amyloid immunotherapy. Lancet Neurol. 2024;23(1):13\u20135.","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"Dyck CH","year":"2023","unstructured":"Van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"ref67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"2","key":"ref68","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1474-4422(23)00508-2","article-title":"A chance to prevent Alzheimer's disease sooner than you think","volume":"23","author":"Reiman EM","year":"2024","unstructured":"Reiman EM, et al. A chance to prevent Alzheimer's disease sooner than you think. Lancet Neurol. 2024;23(2):144\u20135.","journal-title":"Lancet Neurol"},{"issue":"20","key":"ref69","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172882","article-title":"Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders","volume":"134","author":"Kember RL","year":"2024","unstructured":"Kember RL et al. Considerations for the application of polygenic scores to clinical care of individuals with substance use disorders. J Clin Investig, 2024. 134(20).","journal-title":"J Clin Investig"},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1212\/WNL.0b013e318245d295","article-title":"\u03b2-Amyloid burden in healthy aging: regional distribution and cognitive consequences","volume":"78","author":"Rodrigue K","year":"2012","unstructured":"Rodrigue K, et al. \u03b2-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387\u201395.","journal-title":"Neurology"},{"issue":"1","key":"ref71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41576-023-00637-2","article-title":"Principles and methods for transferring polygenic risk scores across global populations","volume":"25","author":"Kachuri L","year":"2024","unstructured":"Kachuri L, et al. Principles and methods for transferring polygenic risk scores across global populations. Nat Rev Genet. 2024;25(1):8\u201325.","journal-title":"Nat Rev Genet"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7911284\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7911284\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:12:09Z","timestamp":1761577929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7911284\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":71,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7911284\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,10,22]]},"subtype":"preprint"}}